国产那格列奈片对2型糖尿病疗效的临床评价

中国临床药理学与治疗学 ›› 2004, Vol. 9 ›› Issue (8): 932-934.

国产那格列奈片对2型糖尿病疗效的临床评价

夏礼斌, 陆美琴, 张斌华, 张安素, 陈月平, 华强, 冒国光¹

皖南医学院弋矶山医院内分泌科, ¹国家药品临床研究基地, 芜湖241001, 安徽

收稿日期:2004-07-22 修回日期:2004-07-25 出版日期:2004-08-26 发布日期:2020-11-20
通讯作者: 夏礼斌,男,硕士,主治医师,研究方向:内分泌与免疫药理学。Tel:0553-5739315 E-mail:xialibin220@yahoo.com.cn

Clinical evaluation on efficacy of domestic nateglinide tablet in patients with type 2 diabetes mellitus

XIA Li-Bin, LU Mei-Qin, ZHANG Bin-Hua, ZHANG An-Su, CHEN Yue-Ping, HUA Qiang, MAO Guo-Guang¹

Department of Endocrinology, ¹National Drug Clinical Research Base, YijishanHospital, Wannan Medical College, Wuhu 241001, Anhui, China

Received:2004-07-22 Revised:2004-07-25 Online:2004-08-26 Published:2020-11-20

摘要/Abstract

摘要： 目的: 评价国产那格列奈片治疗2 型糖尿病的疗效。方法: 46例2型糖尿病患者随机分入那格列奈组和瑞格列奈组,以瑞格列奈作阳性对照,检测空腹血糖及糖化血红蛋白(HbA_1C)。结果: 两组治疗后空腹指尖及静脉血糖、糖化血红蛋白均有所下降,治疗8 周后瑞格列奈组空腹指尖血糖改善值优于那格列奈组。结论: 那格列奈片能改善2 型糖尿病患者的糖代谢,是一种安全有效的降糖药物。

关键词: 那格列奈, 瑞格列奈, 2 型糖尿病, 空腹血糖, 糖化血红蛋白

Abstract: AIM: To evaluate the efficacy of domestic nateglinide tablet with the treatment of patients with type 2 diabetes mellitus (T2DM).METHODS: Forty-six patients of T₂DM were included in this study.The twentythree patients in nateglinide group took nateglinide tablet, and another twenty-three patients in the repaglinide group took repaglinide tablet.The changes of both fasting blood glucose and hemoglobin A_1C(HbA_1C)levels were assayed. RESULTS: After the treatment of 12 weeks, the levels of fasting blood glucose and HbA1C decreased significantly (P<0.01).After 8th weeks, the levels of fasting blood glucose of repaglinide group on finger-tip decreased significantly than those of the nateglinide group.CONCLUSION: Domestic nateglinide, as an effective and safe agent, can improve the glycometabolism in treating T₂DM.

Key words: nateglinide tablet, repaglinide tablet, hemoglobin A_1C, type 2 diabetes mellitus, fasting blood glucose

中图分类号:

夏礼斌, 陆美琴, 张斌华, 张安素, 陈月平, 华强, 冒国光. 国产那格列奈片对2型糖尿病疗效的临床评价[J]. 中国临床药理学与治疗学, 2004, 9(8): 932-934.

XIA Li-Bin, LU Mei-Qin, ZHANG Bin-Hua, ZHANG An-Su, CHEN Yue-Ping, HUA Qiang, MAO Guo-Guang. Clinical evaluation on efficacy of domestic nateglinide tablet in patients with type 2 diabetes mellitus[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(8): 932-934.

参考文献

1 吴万玲.快速胰岛素促泌降糖作用评价[J].国外医学内分泌学分册, 2002;22(3):154
2 廖二元, 超楚生, 主编.内分泌学[M].北京:人民卫生出版社, 2001:1442
3 梁慧芬.内分泌与代谢疾病用药指南[M].美迪医讯亚太有限公司, 2003:170-2
4 Whitelaw DC, Clark PM, Smith JM, Nattrass M.Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus[J].DiabetMed, 2000;17(3):225-9
5 Barnett AH, Anderson DM, Shelley S, Morgan R, Owens DR. A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes[J].Diabetes Obes Metab, 2004;6(2):104-13
6 Gribble FM, Manley SE, Levy JC.Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166)[J].Diabetes Care, 2001;24(7):1221-5
7 Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE.Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control[J].Diabetes Care, 2003;26(6):1685-90
8 Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S.Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes[J].Diabetes Care, 2000;23(11):1660-5
9 Mary F, Carroll, Ahmad I, Katrina R, Mark R, Burge, et al. Control of postprandial hyperglycemia optimal use of short-acting insulin secretagogues[J].Diabetes Care, 2002;25:2147-52
10 Saloranta C, Hershon K, BallM, Dickinson S, Holmes D.Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia[J].Clin Endocrinol Metab, 2002;87(9):4171-6
11 Stefano Del Prato, Robert J, Heine, Leonard K, Christiane G, Sharon G, et al.Emmons treatment of patients over 64 years of age with type 2 diabetes experience from nateglinide pooled database retrospective analysis[J].Diabetes Care, 2003;26(7):2075-80

[1]	孔祥，华强，孟祥健，姚新明，王勇，夏礼斌. 初诊2型糖尿病患者循环miRNA-101的表达变化及临床意义[J]. 中国临床药理学与治疗学, 2017, 22(12): 1406-1409.
[2]	刘长乐, 龚成欣, 熊超鹏, 何鹿玲, 饶燊强, 肖雯, 彭露露, 汤澜, 许永虎, 徐宏. 体重指数影响骨钙素基因HindIII多态性与中国绝经前妇女空腹血糖间的关联[J]. 中国临床药理学与治疗学, 2015, 20(9): 1026-1031.
[3]	王涛, 吕冬梅, 王艳, 宋金方, 鲁茜, 张帆, 李伟, 印晓星. MTNR1B rs10830963基因多态性对瑞格列奈治疗2型糖尿病患者疗效的影响[J]. 中国临床药理学与治疗学, 2015, 20(8): 933-937.
[4]	伍艳, 吴翠芳, 汪江林. 利西拉来治疗2型糖尿病的有效性及安全性的Meta分析[J]. 中国临床药理学与治疗学, 2015, 20(2): 167-174.
[5]	孙旭, 袁钊, 温金华, 熊玉卿. 瑞格列奈药代动力学特征及有关基因多态性对其药代和药物相互作用的影响[J]. 中国临床药理学与治疗学, 2011, 16(4): 468-473.
[6]	金燕, 邱慧, 兰小春, 霍小静. 阿魏酸哌嗪对2型糖尿病血管内皮细胞的保护及功能调节的临床研究[J]. 中国临床药理学与治疗学, 2010, 15(1): 89-92.
[7]	谭鸿毅, 宋敏, 阳国平, 黄志军, 刘畅, 阳丽, 向红, 付志敏, 黄原原. 瑞格列奈在健康人体的药代动力学和药效动力学研究[J]. 中国临床药理学与治疗学, 2009, 14(9): 979-983.
[8]	阳国平, 宋敏, 谭鸿毅, 刘纯, 黄志军, 刘畅, 阳丽, 向红, 付志敏, 黄原原. 有机阴离子转运多肽1B1(OATP1B1)遗传多态性对瑞格列奈药动学的影响[J]. 中国临床药理学与治疗学, 2009, 14(9): 990-994.
[9]	邓阿黎, 向楠, 周忠明, 姜惠中, 张亚兵. 复方中药对多囊卵巢综合征模型大鼠糖代谢的影响[J]. 中国临床药理学与治疗学, 2009, 14(5): 504-508.
[10]	丁平, 竹剑平. 何首乌颗粒治疗2 型糖尿病高脂血症疗效观察[J]. 中国临床药理学与治疗学, 2009, 14(4): 443-447.
[11]	何君, 周巍, 王练词, 何婷晔, 王丹, 范岚, 张伟, 周宏灏. 中国2 型糖尿病人中CYP2C8 、CYP2C9 基因多态性[J]. 中国临床药理学与治疗学, 2009, 14(3): 300-306.
[12]	刘海玲, 谭渊明, 刘昭前. 瘦素抵抗和基因多态性与2型糖尿病的关系[J]. 中国临床药理学与治疗学, 2007, 12(3): 262-265.
[13]	唐平, 杨川, 李莉, 曾映娟, 杜婧. 初发2型糖尿病胰岛素治疗剂量的门诊观察[J]. 中国临床药理学与治疗学, 2006, 11(6): 687-690.
[14]	姜忠, 汤旭磊. 白藜芦醇对2 型糖尿病患者外周血单个核细胞DNA 损伤的体外修复[J]. 中国临床药理学与治疗学, 2006, 11(11): 1285-1290.
[15]	李红辉, 刘恩波, 谢群, 丁殊节, 何涛, 李家富. 罗格列酮与二甲双胍对2 型糖尿病患者血压的影响[J]. 中国临床药理学与治疗学, 2005, 10(6): 717-720.